Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 177Lu-3050
177Lu-IM-3050 · 1 trial · 1 indication
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 6.0, including adverse events (SAEs), AEs leading to discontinuation, and deaths
Type, frequency, seriousness, and severity of AEs graded using the NCI-CTCAE criteria version 6.0, including SAEs, AEs leading to discontinuation, and deaths
| Arm | Type | Description |
|---|---|---|
| Dose Escalation: 177Lu-IM-3050 | EXPERIMENTAL | 177Lu-IM-3050 administered intravenously on a 6-week cycle |
| Dose Expansion: 177Lu-IM-3050 | EXPERIMENTAL | 177Lu-IM-3050 administered intravenously on a 6-week cycle |
| Name | Type | Description |
|---|---|---|
| 177Lu-IM-3050 | DRUG | 177Lu-IM-3050 is a FAP-directed radiopharmaceutical |
Inclusion Criteria: * ≥18 years of age * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1 or 2 * Histological or cytological diagnosis of a solid tumor * Participants must be refractory to or have relapsed after at least one prior standard therapeutic regimen. Participants mu...
177Lu-IM-3050 is an investigational small molecule radiopharmaceutical being developed by Immunome, Inc. for the treatment of solid malignancies. It is currently in Phase 1 clinical development and has not been approved by the FDA. The compound is also known as 177Lu-3050.
177Lu-IM-3050 is being studied for use in patients with solid malignancies. It is an investigational therapy and is not approved for any indication. The Phase 1 trial enrolls adults with advanced cancer.
177Lu-IM-3050 targets fibroblast activation protein, or FAP. It is a small molecule radiopharmaceutical that delivers the radioisotope lutetium-177 to FAP-expressing cells. FAP is a target of interest in solid tumor research.
177Lu-IM-3050 is being developed by Immunome, Inc., which trades on the Nasdaq under the ticker IMNM. Immunome is the sponsor of the Phase 1 clinical trial evaluating the compound in advanced cancer.
177Lu-IM-3050 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 study is currently recruiting participants.
177Lu-IM-3050 is being evaluated in one Phase 1 clinical trial, NCT07505771, titled A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer. The trial is recruiting up to 105 adult participants in the United States.
Yes, 177Lu-IM-3050 and 177Lu-3050 refer to the same investigational compound. 177Lu-3050 is an alternative name for the drug being developed by Immunome, Inc. for solid malignancies.